

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial

683 patients with aggressive B-non Hodgkin lymphoma in first complete remission

diffuse large B-cell lymphoma N=662
follicular lymphoma grade 3b N=21

randomisation

rituximab maintenance

N=338

observation

N=345

Event-free survival
(primary endpoint)*



80.1

76.5

p=0.0670

Progression-free survival
(secondary endpoint)



86.3

79.0

p=0.3646

Overall-free survival
(secondary endpoint)



92.0

90.3

p=0.3184

0 25 50 75 100

0 25 50 75 100

* Male patients benefited from rituximab maintenance regarding event-free survival

Differences were not significant for the intent to treat population